Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment

ACS Nano

Volumn 8, Issue 4, 2014, Pages 3636-3645

  Xu, Zhenghong ^a   Wang, Yuhua ^a   Zhang, Lu ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

immunotherapy; melanoma; nanoparticle; peptide vaccine; tumor microenvironment

Indexed keywords

ANTIGENS; DERMATOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; HYALURONIC ACID; IMMUNE SYSTEM; NANOPARTICLES; OLIGONUCLEOTIDES; ONCOLOGY; PEPTIDES; VACCINES;

CANCER IMMUNOTHERAPY; CPG OLIGONUCLEOTIDES; IMMUNOTHERAPY; MELANOMA; PEPTIDE VACCINES; STRATEGY DEVELOPMENT; TRANSFORMING GROWTH FACTORS; TUMOR MICROENVIRONMENT;

TUMORS;

CALCIUM PHOSPHATE; CYTOKINE; DRUG CARRIER; HYALURONIC ACID; NANOPARTICLE; PROTAMINE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANIMAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHEMISTRY; DEFICIENCY; DENDRITIC CELL; DISEASE COURSE; DOWN REGULATION; FEMALE; GENETICS; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CALCIUM PHOSPHATES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; DOWN-REGULATION; DRUG CARRIERS; FEMALE; HYALURONIC ACID; MELANOMA, EXPERIMENTAL; MICE; NANOPARTICLES; PROTAMINES; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 84899457547     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn500216y     Document Type: Article

References (36)

1. Mellman, I.; Coukos, G.; Dranoff, G. Cancer Immunotherapy Comes of Age Nature 2011, 480, 480-489
2. Dougan, M.; Dranoff, G. Immune Therapy for Cancer Annu. Rev. Immunol. 2009, 27, 83-117
3. Andrews, D. M.; Maraskovsky, E.; Smyth, M. J. Cancer Vaccines for Established Cancer: How To Make Them Better? Immunol. Rev. 2008, 222, 242-255
4. Liotta, L. A.; Kohn, E. C. The Microenvironment of the Tumour-Host Interface Nature 2001, 411, 375-379
5. Devaud, C.; John, L. B.; Westwood, J. A.; Darcy, P. K.; Kershaw, M. H. Immune Modulation of the Tumor Microenvironment for Enhancing Cancer Immunotherapy OncoImmunology 2013, 2, e25961
6. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an Emerging Platform for Cancer Therapy Nat. Nanotechnol. 2007, 2, 751-760
7. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in Medicine: Therapeutic Applications and Developments Clin. Pharmacol. Ther. 2008, 83, 761-769
8. Shi, J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications Nano Lett. 2010, 10, 3223-3230
9. Zhang, Z.; Tongchusak, S.; Mizukami, Y.; Kang, Y. J.; Ioji, T.; Touma, M.; Reinhold, B.; Keskin, D. B.; Reinherz, E. L.; Sasada, T. Induction of Anti-Tumor Cytotoxic T Cell Responses through Plga-Nanoparticle Mediated Antigen Delivery Biomaterials 2011, 32, 3666-3678
10. Hamdy, S.; Molavi, O.; Ma, Z.; Haddadi, A.; Alshamsan, A.; Gobti, Z.; Elhasi, S.; Samuel, J.; Lavasanifar, A. Co-Delivery of Cancer-Associated Antigen and Toll-Like Receptor 4 Ligand in Plga Nanoparticles Induces Potent Cd8+ T Cell-Mediated Anti-Tumor Immunity Vaccine 2008, 26, 5046-5057
11. Jerome, V.; Graser, A.; Muller, R.; Kontermann, R. E.; Konur, A. Cytotoxic T Lymphocytes Responding to Low Dose Trp2 Antigen Are Induced against B16 Melanoma by Liposome-Encapsulated Trp2 Peptide and Cpg DNA Adjuvant J. Immunother. 2006, 29, 294-305
12. Sheng, W. Y.; Huang, L. Cancer Immunotherapy and Nanomedicine Pharm. Res. 2011, 28, 200-214
13. Melief, C. J.; Van Der Burg, S. H.; Toes, R. E.; Ossendorp, F.; Offringa, R. Effective Therapeutic Anticancer Vaccines Based on Precision Guiding of Cytolytic T Lymphocytes Immunol. Rev. 2002, 188, 177-182
14. Xu, Z.; Ramishetti, S.; Tseng, Y. C.; Guo, S.; Wang, Y.; Huang, L. Multifunctional Nanoparticles Co-Delivering Trp2 Peptide and Cpg Adjuvant Induce Potent Cytotoxic T-Lymphocyte Response against Melanoma and Its Lung Metastasis J. Controlled Release 2013, 172, 259-265
15. Wang, Y.; Xu, Z.; Guo, S.; Zhang, L.; Sharma, A.; Robertson, G. P.; Huang, L. Intravenous Delivery of Sirna Targeting Cd47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis Mol. Ther. 2013, 21, 1919-1929
16. Chen, W.; Huang, L. Induction of Cytotoxic T-Lymphocytes and Antitumor Activity by a Liposomal Lipopeptide Vaccine Mol. Pharmaceutics 2008, 5, 464-471
17. Grasso, F.; Negri, D. R.; Mochi, S.; Rossi, A.; Cesolini, A.; Giovannelli, A.; Chiantore, M. V.; Leone, P.; Giorgi, C.; Cara, A. Successful Therapeutic Vaccination with Integrase Defective Lentiviral Vector Expressing Nononcogenic Human Papillomavirus E7 Protein Int. J. Cancer 2013, 132, 335-344
18. Xiang, S. D.; Wilson, K.; Day, S.; Fuchsberger, M.; Plebanski, M. Methods of Effective Conjugation of Antigens to Nanoparticles as Non-Inflammatory Vaccine Carriers Methods 2013, 60, 232-241
19. Whiteside, T. L. The Tumor Microenvironment and Its Role in Promoting Tumor Growth Oncogene 2008, 27, 5904-5912
20. Zagury, D.; Gallo, R. C. Anti-Cytokine Ab Immune Therapy: Present Status and Perspectives Drug Discovery Today 2004, 9, 72-81
21. Tamada, K.; Chen, L. Renewed Interest in Cancer Immunotherapy with the Tumor Necrosis Factor Superfamily Molecules Cancer Immunol. Immunother. 2006, 55, 355-362
22. Sabel, M. S.; Skitzki, J.; Stoolman, L.; Egilmez, N. K.; Mathiowitz, E.; Bailey, N.; Chang, W. J.; Chang, A. E. Intratumoral Il-12 and Tnf-Alpha-Loaded Microspheres Lead to Regression of Breast Cancer and Systemic Antitumor Immunity Ann. Surg. Oncol. 2004, 11, 147-156
23. Balkwill, F. Tnf-Alpha in Promotion and Progression of Cancer Cancer Metastasis Rev. 2006, 25, 409-416
24. Yang, L.; Moses, H. L. Transforming Growth Factor Beta: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer? Cancer Res. 2008, 68, 9107-9111
25. Connolly, E. C.; Freimuth, J.; Akhurst, R. J. Complexities of Tgf-Beta Targeted Cancer Therapy Int. J. Biol. Sci. 2012, 8, 964-978
26. Kim, S.; Buchlis, G.; Fridlender, Z. G.; Sun, J.; Kapoor, V.; Cheng, G.; Haas, A.; Cheung, H. K.; Zhang, X.; Corbley, M. et al. Systemic Blockade of Transforming Growth Factor-Beta Signaling Augments the Efficacy of Immunogene Therapy Cancer Res. 2008, 68, 10247-10256
27. Li, M. O.; Wan, Y. Y.; Sanjabi, S.; Robertson, A. K.; Flavell, R. A. Transforming Growth Factor-Beta Regulation of Immune Responses Annu. Rev. Immunol. 2006, 24, 99-146
28. Gorelik, L.; Flavell, R. A. Transforming Growth Factor-Beta in T-Cell Biology Nat. Rev. Immunol. 2002, 2, 46-53
29. Li, M. O.; Flavell, R. A. Tgf-Beta: A Master of All T Cell Trades Cell 2008, 134, 392-404
30. Wahl, S. M.; Wen, J.; Moutsopoulos, N. Tgf-Beta: A Mobile Purveyor of Immune Privilege Immunol. Rev. 2006, 213, 213-227
31. Thomas, D. A.; Massague, J. Tgf-Beta Directly Targets Cytotoxic T Cell Functions during Tumor Evasion of Immune Surveillance Cancer Cell 2005, 8, 369-380
32. von Boehmer, H. Mechanisms of Suppression by Suppressor T Cells Nat. Immunol. 2005, 6, 338-344
33. Liu, Z.; Kim, J. H.; Falo, L. D., Jr.; You, Z. Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity J. Immunol. 2009, 182, 6160-6167
34. Wan, Y. Y.; Flavell, R. A. Tgf-Beta and Regulatory T Cell in Immunity and Autoimmunity J. Clin. Immunol. 2008, 28, 647-659
35. Gabrilovich, D. I.; Nagaraj, S. Myeloid-Derived Suppressor Cells as Regulators of the Immune System Nat. Rev. Immunol. 2009, 9, 162-174
36. Vasievich, E. A.; Chen, W.; Huang, L. Enantiospecific Adjuvant Activity of Cationic Lipid Dotap in Cancer Vaccine Cancer Immunol. Immunother. 2011, 60, 629-638